Latest & greatest articles for risperidone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on risperidone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on risperidone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for risperidone

41. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise

Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise Heeg B M, Antunes J, Figueira M L, Jara J M, Marques Teixeira J, Palha A P, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto C, Van Hout B A Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of long-acting risperidone (LAR) as first-line treatment of schizophrenia compared with conventional haloperidol depot and oral risperidone. The authors concluded that treatment with LAR might be cost

NHS Economic Evaluation Database.2008

42. Treatment-resistant depression: adding low dose risperidone improves symptoms

Treatment-resistant depression: adding low dose risperidone improves symptoms Treatment-resistant depression: adding low dose risperidone improves symptoms | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Treatment-resistant depression: adding low dose risperidone improves symptoms Article Text Therapeutics Treatment-resistant depression: adding low dose risperidone improves symptoms Statistics from Altmetric.com No Altmetric data available for this article. Request permissions If you wish to reuse any or all of this article please use the link

Evidence-Based Mental Health2008

43. Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment

Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment Article Text Therapeutics Little difference between haloperidol, risperidone and olanzapine in weight gain after 1 year of treatment Statistics from Altmetric.com No Altmetric data available

Evidence-Based Mental Health2008

44. Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial.

Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. 18177776 2008 01 07 2008 01 17 2015 07 08 1474-547X 371 9606 2008 Jan 05 Lancet (London, England) Lancet Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: a randomised controlled trial. 57-63 10.1016/S0140-6736(08)60072-0 Aggressive challenging (...) behaviour is frequently reported in adults with intellectual disability and it is often treated with antipsychotic drugs. However, no adequate evidence base for this practice exists. We compared flexible doses of haloperidol (a typical, first-generation antipsychotic drug), risperidone (an atypical, second-generation antipsychotic), and placebo, in the treatment of this behaviour. 86 non-psychotic patients presenting with aggressive challenging behaviour from ten centres in England and Wales, and one

Lancet2008

45. Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks

Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Olanzapine and risperidone may improve neurocognition more than haloperidol in people with schizophrenia who continue treatment for 52 weeks Article Text Therapeutics Olanzapine and risperidone may improve

Evidence-Based Mental Health2007

47. Discontinuing risperidone results in relapse in children with autism spectrum disorders

Discontinuing risperidone results in relapse in children with autism spectrum disorders Discontinuing risperidone results in relapse in children with autism spectrum disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Discontinuing risperidone results in relapse in children with autism spectrum disorders Article Text Therapeutics Discontinuing risperidone results in relapse in children with autism spectrum disorders Statistics from Altmetric.com No Altmetric data available for this article. Troost PW, Lahuis BE, Steenhuis MP, et al

Evidence-Based Mental Health2007

48. Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia

Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Article Text Therapeutics Adding sarcosine, but not D-serine, to risperidone improves symptoms in people with acute phase schizophrenia Statistics from Altmetric.com

Evidence-Based Mental Health2007

49. Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder

Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder Article Text Therapeutics Risperidone effectively increases rates of symptomatic remission of acute mania in people with bipolar disorder Statistics from

Evidence-Based Mental Health2007

50. Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents

Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents Article Text Therapeutics Risperidone improves restricted, repetitive, and stereotyped behaviour in autistic children and adolescents Statistics from Altmetric.com No Altmetric

Evidence-Based Mental Health2007

51. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia

Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia Bounthavong M, Okamoto M P Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined three drug treatments for patients with schizophrenia. Specifically, a conventional antipsychotic, haloperidol (HAL), and two newer atypical antipsychotics, risperidone (RIS) and olanzapine (OLA). The dosages assumed were 15 mg/day

NHS Economic Evaluation Database.2007

52. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care

Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care Niaz O S, Haddad P M Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of risperidone long-acting injection (RLAI), compared with conventional oral antipsychotics, for patients with schizophrenia. RLAI (50 mg) was administered once every 2 weeks. Type

NHS Economic Evaluation Database.2007

53. Risperidone in long-term treatment for bipolar disorder.

Risperidone in long-term treatment for bipolar disorder. BACKGROUND: Risperidone, an atypical antipsychotic, is used to treat acute manic episodes, particularly when psychotic symptoms are present. Drugs used to treat mania are often continued as long-term treatment to prevent relapse. There is a need for evidence of the effectiveness and safety of risperidone as long-term treatment. OBJECTIVES: To assess the randomised evidence for the efficacy and tolerability of risperidone compared (...) searched; researchers in the field were contacted. SELECTION CRITERIA: Randomised trials comparing risperidone with placebo or other drug in long-term treatment for prevention of depressive or manic relapses. DATA COLLECTION AND ANALYSIS: Not applicable. MAIN RESULTS: No randomised trials comparing risperidone with other treatments for the prevention of manic and depressive relapses were identified. AUTHORS' CONCLUSIONS: There is a need for randomised controlled trials comparing risperidone and other

Cochrane2006

54. Risperidone augmentation of clozapine: a critical review

Risperidone augmentation of clozapine: a critical review Risperidone augmentation of clozapine: a critical review Risperidone augmentation of clozapine: a critical review Kontaxakis V P, Ferentinos P P, Havaki-Kontaxaki B J, Paplos K G, Pappa D A, Christodoulou G N CRD summary The authors concluded that existing evidence encourages the use of risperidone as augmentation of clozapine (CLZ) in at least a group of CLZ-resistant patients. Given the absence of a formal validity assessment (...) and methodological limitations in the review process and analysis, the authors' conclusions should be treated with caution. Authors' objectives To review the literature on the efficacy and safety of risperidone (RIS) as an adjunctive agent in clozapine (CLZ)-resistant patients with schizophrenia or schizoaffective disorder. Searching MEDLINE was searched from January 1988 to June 2005; the search terms were reported. The references of identified papers and reviews were checked. Study selection Studies of RIS

DARE.2006

55. A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany

A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany Beard A M, Maciver F, Clouth J, Ruther E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared the use of olanzapine with risperidone in the treatment of patients with an established history of schizophrenia. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients currently

NHS Economic Evaluation Database.2006

56. Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone

Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Article Text Therapeutics Schizophrenia: risperidone and olanzapine increase time to discontinuation compared with quetiapine and ziprasidone Statistics from

Evidence-Based Mental Health2006

57. Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders

Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive behaviour disorders Article Text Therapeutics Risperidone maintenance treatment increases time to symptom recurrence in young people with disruptive

Evidence-Based Mental Health2006

58. Clozapine alone versus clozapine and risperidone with refractory schizophrenia.

Clozapine alone versus clozapine and risperidone with refractory schizophrenia. 16452559 2006 02 02 2006 02 07 2013 11 21 1533-4406 354 5 2006 Feb 02 The New England journal of medicine N. Engl. J. Med. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. 472-82 The treatment of schizophrenia with multiple antipsychotic drugs is common, but the benefits and risks are not known. In a randomized, double-blind study, we evaluated patients with schizophrenia and a poor (...) response to treatment with clozapine. The patients continued to take clozapine and were randomly assigned to receive eight weeks of daily augmentation with 3 mg of risperidone or with placebo. This course of treatment was followed by an optional 18 weeks of augmentation with risperidone. The primary outcome was reduction in the total score for severity of symptoms on the Positive and Negative Syndrome Scale (PANSS). The secondary outcomes included cognitive functioning. A total of 68 patients were

NEJM2006

59. Risperidone improves severe tardive dyskinesia in people with schizophrenia

Risperidone improves severe tardive dyskinesia in people with schizophrenia Risperidone improves severe tardive dyskinesia in people with schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log (...) in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Risperidone improves severe tardive dyskinesia in people with schizophrenia Article Text Therapeutics Risperidone improves severe tardive dyskinesia in people with schizophrenia Free Rajiv Tandon , MD Statistics from Altmetric.com No Altmetric data available for this article. Bai Y-M, Yu S-C, Lin C-C. Risperidone for severe tardive dyskinesia

Evidence-Based Mental Health2005

60. A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials

A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials A comparison of olanzapine versus risperidone for the treatment of schizophrenia: a meta-analysis of randomised clinical trials Mudge M A, Davey P J, Coleman K A, Montgomery W, Croker V S, Mullen K, Castle D J CRD summary This review concluded (...) that olanzapine was superior to risperidone for a number of efficacy and safety variables, and these advantages may convey clinical relevance to certain aspects of schizophrenia. A lack of a systematic quality assessment and no details of the review methodology suggest that this conclusion should be treated with caution. Authors' objectives To compare the efficacy and safety of olanzapine with risperidone in the treatment of schizophrenia. Searching MEDLINE, EMBASE and the Cochrane Controlled Trials Register

DARE.2005